These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19251336)

  • 1. Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature.
    Swinnen SG; DeVries JH
    Diabetes Res Clin Pract; 2009 May; 84(2):e24-6. PubMed ID: 19251336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
    Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
    Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
    Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: trial comparing insulin detemir with insulin glargine.
    Swinnen S; Holleman F
    Clin Ther; 2009 May; 31(5):1124-5; author reply 1125-6. PubMed ID: 19539113
    [No Abstract]   [Full Text] [Related]  

  • 7. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
    Dailey G; Admane K; Mercier F; Owens D
    Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary.
    Reynolds LR
    Postgrad Med; 2010 Jan; 122(1):201-3. PubMed ID: 20107306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine.
    Fadini GP; de Kreutzenberg SV; Mariano V; Boscaro E; Bertolini F; Mancuso P; Quarna J; Marescotti M; Agostini C; Tiengo A; Avogaro A
    Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
    Swinnen SG; Dain MP; Aronson R; Davies M; Gerstein HC; Pfeiffer AF; Snoek FJ; Devries JH; Hoekstra JB; Holleman F
    Diabetes Care; 2010 Jun; 33(6):1176-8. PubMed ID: 20200301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of insulin detemir in overweight type 2 diabetes management.
    Demssie YN; Younis N; Soran H
    Vasc Health Risk Manag; 2009; 5(3):553-60. PubMed ID: 19590589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between long-acting insulins for the treatment of type 2 diabetes.
    Jensen MG; Hansen M; Brock B; Rungby J
    Expert Opin Pharmacother; 2010 Aug; 11(12):2027-35. PubMed ID: 20642370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.